CFM
OLMA icon

Catalyst Funds Management’s Olema Pharmaceuticals OLMA Stock Holding History

Catalyst Funds Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,900
Closed -$20.6K – 1524
2024
Q2 		$20.6K Sell
1,900
-6,427
-77% -$69.7K 0.01% 672
2024
Q1 		$94.3K Buy
+8,327
New +$107K 0.03% 405

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Catalyst Funds Management's OLMA Position: Q3 2024 in Review

Catalyst Funds Management sold out of Olema Pharmaceuticals (OLMA) in Q3 2024, closing a stake of 1,900 shares — an estimated $20.6K sold.

Catalyst Funds Management first reported a position in OLMA in Q1 2024 and held it in 2 quarters. The position peaked at $94.3K in Q1 2024. 130 funds tracked by Wall St. Rank hold OLMA as of Q3 2024.

  • Catalyst Funds Management reported no remaining Olema Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,900 Olema Pharmaceuticals shares in Q3 2024, an estimated $20.6K.
  • Catalyst Funds Management first reported a position in Olema Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Olema Pharmaceuticals position peaked at $94.3K in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.